(Health Korea News / Yoo Ji-in) Alteogen and Peptron’s stock prices plummeted as they were engulfed in negative rumors.
According to the Korea Exchange on the 22nd, Alteogen closed at 292,000 won, a plunge of 15.73% that day. Rumors that Halozyme Therapeutics (Halozyme) of the United States will file a patent lawsuit against Alteogen seem to have had an impact.
Alteogen transferred its platform technology to Merck (MSD), a large global pharmaceutical company, in exchange for $4.317 billion (approximately KRW 6.0675 trillion). However, there was a possibility that ALT-B4, a technology-transferred subcutaneous injection (SC) change platform, may have infringed on Halozyme’s ‘MDASE’ patent.
In response, Alteogen denies the possibility of patent infringement, but shareholders’ anxiety is growing. On the 12th (local time), MSD filed a ‘post-registration patent revocation (PGR)’ for Halozyme’s ‘MDASE’ patent with the United States Patent and Trademark Office (USPTO). It is analyzed that preemptive measures have been taken in preparation for Halozyme’s patent infringement lawsuit.
The news that Alteogen is pursuing the issuance of redeemable convertible preferred stock (RCPS) worth 200 billion won is also having a negative impact on the stock price.
Peptron plummeted by a whopping 25.0% on the 22nd, hitting the lowest price at one point during the day as concerns about the recently concluded contract spread in the market. The stock price fell from 105,200 won to 78,900 won. The company explained the market’s concerns through a notice on its website that day.
In the notice, “We ask for your deep understanding for not being able to explain in detail the ongoing content of technology transfer and platform expansion due to confidentiality provisions with the contract counterparty,” and “Our technology is a technology that lasts for more than one month. “It has been evaluated as the optimal technology that can be directly applied to drugs, and we are closely discussing specific issues for commercialization and production.”
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
